Education
About Us
Working with TipRanks
Follow Us
Zynex Inc (ZYXI)
:ZYXI
ZYXI Stock Chart & Stats
$1.34
-$0.09(-1.11%)
At close: 4:00 PM EST
$1.34
-$0.09(-1.11%)
Day’s Range― - ―
52-Week Range$0.38 - $8.72
Previous CloseN/A
Volume7.23K
Average Volume (3M)9.44M
Market Cap
$37.38M
Enterprise Value$102.31M
Total Cash (Recent Filing)$13.26M
Total Debt (Recent Filing)$71.62M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Feb 26, 2026EPS EstimateN/A
Last Dividend Ex-Date
Jan 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding30,388,636
10 Day Avg. Volume27,893,957
30 Day Avg. Volume9,443,059
Financial Highlights & Ratios
PEG Ratio-1.28
Price to Book (P/B)7.16
Price to Sales (P/S)1.33
P/FCF Ratio21.07
Enterprise Value/Market Cap2.74
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda-1.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$91.80M
Bulls Say, Bears Say
Bulls Say
Leadership ChangeSteven Dyson, with over 25 years of experience in the medical technology sector, has been appointed as CEO to refocus Zynex's business strategy and return it to a strong growth trajectory.
Market ExpansionNiCO, if cleared by the FDA, would allow Zynex to enter the $2.8 billion pulse oximetry market with differentiating precision and accuracy in hospital and non-hospital settings.
Bears Say
Potential DilutionPotential dilution risk is noted as a concern for Zynex's stock value.
Regulatory RisksRisks include slower-than-anticipated revenue growth due to competition and inability to secure regulatory clearance for other medical devices.
Revenue DeclineTotal revenue was $22.3M, representing 55% YoY decline and missing our projection of $27.0M.
Zynex News
ZYXI FAQ
What was Zynex Inc’s price range in the past 12 months?
Zynex Inc lowest stock price was $0.38 and its highest was $8.72 in the past 12 months.
What is Zynex Inc’s market cap?
Zynex Inc’s market cap is $37.38M.
When is Zynex Inc’s upcoming earnings report date?
Zynex Inc’s upcoming earnings report date is Feb 26, 2026 which is in 85 days.
How were Zynex Inc’s earnings last quarter?
Zynex Inc released its earnings results on Nov 18, 2025. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$1.23.
Is Zynex Inc overvalued?
According to Wall Street analysts Zynex Inc’s price is currently Overvalued.
Does Zynex Inc pay dividends?
Zynex Inc pays a Notavailable dividend of $0.091 which represents an annual dividend yield of N/A. See more information on Zynex Inc dividends here
What is Zynex Inc’s EPS estimate?
Zynex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zynex Inc have?
Zynex Inc has 30,388,636 shares outstanding.
What happened to Zynex Inc’s price movement after its last earnings report?
Zynex Inc reported an EPS of -$1.42 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Zynex Inc?
Currently, no hedge funds are holding shares in ZYXI
Zynex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
ZYXI Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 6.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-64.05%
Trailing 12-Months
Company Description
Zynex Inc
Zynex, Inc. (NASDAQ: ZYXI) is a medical technology company that specializes in the development and commercialization of innovative medical devices for pain management and rehabilitation. The company primarily operates in the healthcare sector, focusing on electrical stimulation devices that provide non-invasive solutions for patients suffering from chronic pain and other conditions requiring rehabilitation. Zynex's core products include its NexWave and InWave devices, which are designed to improve patient outcomes through advanced technology in electrotherapy and muscle stimulation.
ZYXI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call presents a challenging financial situation for Zynex, Inc., marked by significant revenue decline, negative cash flow, and substantial net losses. Despite the introduction of a new management team and initiatives to improve sales productivity and compliance, the financial strain and need for debt restructuring are critical hurdles.View all ZYXI earnings summariesZYXI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Henry Schein
―
Owens & Minor
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Wellgistics Health Inc
―
Ownership Overview
43.09% Insiders
4.13% Mutual Funds
1.14% Other Institutional Investors
48.69% Public Companies and
Individual Investors